Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply
Lancet Diabetes Endocrinol
.
2017 May;5(5):330.
doi: 10.1016/S2213-8587(17)30110-9.
Author
Christopher Sorli
1
Affiliation
1
Billings Clinic, Billings, MT 59101, USA. Electronic address: chrissorli@gmail.com.
PMID:
28434491
DOI:
10.1016/S2213-8587(17)30110-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Glucagon-Like Peptides*
Humans
Lipids
Non-alcoholic Fatty Liver Disease*
Substances
Lipids
semaglutide
Glucagon-Like Peptides